SCHEMBL2077501

SCHEMBL2077501

Cn1nc(-c2ccc(F)cc2)c(CCl)c1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
ALDH1A1 P00352 1/20 0.45
MAPT P10636 3/20 0.44
LMNA P02545 1/20 0.44
MAPK14 Q16539 2/20 0.42
GAA P10253 1/20 0.42
CSNK1D P48730 2/20 0.41
CSNK1E P49674 2/20 0.41
MAPK13 O15264 1/20 0.41
MAPK12 P53778 1/20 0.41
MAPK11 Q15759 1/20 0.41
SLC34A1 Q06495 5/20 0.40
RECQL P46063 2/20 0.38
KMT2A Q03164 1/20 0.37
MAP4K4 O95819 1/20 0.37
EGFR P00533 1/20 0.37
FRK P42685 1/20 0.37
MAPK9 P45984 1/20 0.37
CSNK1A1 P48729 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2076868 0.83 NPSR1 (0.66) TDP1NPSR1ALDH1A1MAPTLMNA
SCHEMBL2079138 0.74 TDP1 (0.48) TDP1NPSR1ALDH1A1MAPTLMNA
SCHEMBL15331476 0.73 KMT2A (0.42) TDP1ALDH1A1MAPTMAPK14CSNK1D
Hydrochloric Acid SCHEMBL2079527 0.73 TDP1 (0.47) TDP1NPSR1ALDH1A1MAPTLMNA
SCHEMBL20074676 0.71 MAPK14 (0.56) MAPK14CSNK1DCSNK1EMAPK13MAPK12
SCHEMBL14191068 0.70 NPSR1 (0.66) TDP1NPSR1ALDH1A1MAPTLMNA
SCHEMBL20074876 0.70 MAPK14 (0.59) NPSR1ALDH1A1LMNAMAPK14CSNK1D
SCHEMBL2077156 0.69 TDP1 (0.64) TDP1NPSR1ALDH1A1MAPTLMNA
SCHEMBL14039836 0.69 MAPK14 (0.43) NPSR1ALDH1A1MAPK14CSNK1DCSNK1E
SCHEMBL16200381 0.68 MAPK14 (0.46) MAPK14CSNK1DCSNK1EMAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110059964-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2011-03-10 US disclosed
US-7659298-B2 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethylsulphanyl)-N-quinolin-3-ylbenzamide; 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethoxy)-N-naphthalin-2-ylbenzamide; obesity, including obesity of the non-insuline-dependent diabetes patients, sleeping disorders, stroke, nausea and vomiting SANOFI-AVENTIS (FR) 2010-02-09 US disclosed
EP-1699454-B1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS SANOFI AVENTIS (FR) 2009-08-05 EP disclosed
US-20070021459-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2007-01-25 US disclosed
EP-1699454-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS Sanofi-Aventis (FR) 2006-09-13 EP disclosed
WO-2005060959-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021459-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY1R TDP1 4727/4885NPSR1 8/4885ALDH1A1 2239/4885
US-20110059964-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY1R TDP1 4727/4885NPSR1 8/4885ALDH1A1 2239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.